Plain-English translation of NCT07132515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether blood-thinning medications—such as Enoxaparin, warfarin, or apixaban—can safely and effectively treat blood clots that form in the portal vein of patients with advanced liver disease. The study will compare outcomes in patients who receive the medication versus those who do not, and will also look at how the medication works differently in patients with and without liver cancer.
Blood clots in the portal vein are a serious complication of advanced liver disease, but doctors are not yet certain whether blood-thinning treatment is safe and beneficial for these patients, especially those with liver cancer. This trial aims to provide clear answers about whether this medication can help prevent complications and improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be placed into one of three groups: patients receiving blood-thinning medication with liver cancer, patients receiving the medication without liver cancer, or patients not receiving the medication. You will be monitored regularly to see how well the medication works, whether your blood clot improves or stays the same, and whether you experience any side effects. The study team will track your health outcomes over time to compare the different treatment approaches.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Egypt
Phase
Post-approval monitoring
Sponsor
Mansoura University
Enrollment target
~100 participants
Started
August 2023
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dalia Elsayed Ganady, MBBS
Mansoura University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.